The era of targeted therapy for hyperlipidemia
Despite a variety of lipid-lowering drugs, mostly pelleted, aimed at reducing low-density lipoprotein cholesterol and triglycerides, only a small number of patients achieve their target levels. The reasons are insufficient adherence to treatment, rare use of combined lipid-lowering therapy regimens...
Saved in:
| Main Authors: | U. V. Chubykina, A. V. Tyurina, M. V. Ezhov |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2024-10-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/6038 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prevalence of familial hypercholesterolemia and hyperlipoproteinemia(a) in patients with premature acute coronary syndrome
by: U. V. Chubykina, et al.
Published: (2022-07-01) -
Review and analysis of 2023 Clinical Guidelines for Lipid Metabolism Disorders
by: I. V. Sergienko, et al.
Published: (2023-12-01) -
Eurasian Association of Cardiology (EAC)/ Russian National Atherosclerosis Society (RNAS) Guidelines for the diagnosis and correction of dyslipidemia for the prevention and treatment of atherosclerosis (2025)
by: M. V. Ezhov, et al.
Published: (2025-06-01) -
Impact of hyperlipoproteinemia(a) on the diagnosis of familial hypercholesterolemia and cardiovascular risk assessment
by: A. M. Namitokov, et al.
Published: (2025-04-01) -
Editorial: TRLs (triglycerides-rich lipoproteins): a new target for atherosclerosis
by: Mei Dong, et al.
Published: (2025-01-01)